The mRNA-1283 vaccine demonstrated higher efficacy in adults aged 18 years and above.Moderna has announced that its Phase III clinical trial of the investigational next-generation Covid-19 vaccine, mRNA-1283, met its primary efficacy endpoint.The vaccine demonstrated non-inferior efficacy against Covid-19 compared to Spikevax (mRNA-1273).Notably, the trial observed higher efficacy in adults aged 18 years and above, […]
